|
抗凝血酶治疗弥散性血管内凝血的研究进展 |
|
nbsp;to plasmaderived antithrombin regardless of different Nglycosylation[J].Thromb Res,2007,119(5):631641.
[4] EISELE B,LAMY M,THIJS LG,et al.Antithrombin III in patients with severe sepsis.A randomized,placebocontrolled,doubleblind multicenter trial plus a metaanalysis on all randomized,placebocontrolled,doubleblind trials with antithrombin III in severe sepsis[J].Intensive Care Med,1998,24(7): 663672.
[5] INTHORN D,HOFFMANN JN,HATL WH,et al.Effect of antithrombin III supplementation on inflammatory response in patients with severe sepsis[J].Shock,1998,10(2):9096.
[6] NIESSEN RW,LAMPING RJ,JANSEN PM,et al.Antithrombin acts as a negative acute phase protein as established with studies on HepG2 cells and in baboons[J]. Thromb Haemost, 1997,78(3):10881092.
[7] OKAJIMA K,UCHIBA M.The antiinflammatory properties of antithrombin III: new therapeutic implications[J]. Semin Thromb Hemost,1998,24(1):2732.
[8] MINNEMA MC,ChANG AC,JANSEN PM,et al. Recombinant human antithrombin III improves survival and attenuates inflammatory responses in baboons lethally challenged with Escherichia coli [J]. Blood,2000,95(4):11171123.
[9] ESMON CT.Are nature anticoaguLants candidates for modulating the inflammatory response to endotoxin [J].Blood,2000,95:11131116.
[10] C上一页 [1] [2] [3] [4] [5] [6] 下一页 上一个医学论文: CD 40 CD 40L与血栓性疾病研究进展 下一个医学论文: 产科弥散性血管内凝血
|
|
|